文献速递胰腺与胆道疾病消化道肿瘤与早癌消化内镜

支架内射频消融联合无覆膜金属支架置入治疗远端恶性胆道梗阻中因肿瘤内生长/过度生长导致自膨式金属支架闭塞的多中心倾向评分匹配研究

In-stent radiofrequency ablation with uncovered metal stent placement for tumor ingrowth/overgrowth causing self-expandable metal stent occlusion in distal malignant biliary obstruction: multicenter propensity score-matched study.
PubMed 文献 · Gastrointest Endosc · 2022-11-30

本研究纳入2016至2020年3家三级医院48例因胰胆管癌置入自膨式金属支架(SEMS)后肿瘤内生长或过度生长导致复发性胆道梗阻的患者,比较支架内射频消融(IS-RFA)后置入无覆膜SEMS与单纯置入无覆膜SEMS的疗效。倾向评分1:1匹配后,RFA组中位至复发性胆道梗阻时间(TRBO)为117天,对照组为82.5天(P = .029);两组中位总生存期无显著差异(170天 vs 72天;P = .902)。结论认为IS-RFA后置入无覆膜SEMS安全可行,作为闭塞SEMS的支架翻修可能改善TRBO。

要点

  • RFA组中位TRBO为117天,对照组为82.5天(P = .029)。
  • 两组中位总生存期无显著差异(170天 vs 72天;P = .902)。
  • RFA组5例(35.7%)因支架内接触中断消融,同次重复后92.9%患者获得足够消融能量。

核心结论

  • IS-RFA后置入无覆膜SEMS安全可行,作为胰胆管癌闭塞SEMS的支架翻修可能改善TRBO。

研究设计与样本

  • 多中心倾向评分匹配研究,纳入2016至2020年3家三级医院48例因胰胆管癌置入SEMS后肿瘤内生长或过度生长导致复发性胆道梗阻的患者。
  • RFA组接受IS-RFA联合无覆膜SEMS置入,对照组仅接受无覆膜SEMS置入,两组按倾向评分1:1匹配。

主要发现

  • RFA组中位TRBO为117天,对照组为82.5天(P = .029)。
  • 两组中位总生存期无显著差异(170天 vs 72天;P = .902)。
  • 第二次SEMS置入后两组均未报告显著不良事件,对照组报告2例轻度胆管炎。
  • RFA组5例(35.7%)因支架内接触中断消融,同次重复IS-RFA后92.9%患者获得足够消融能量。

临床怎么用

  • 原文结论认为IS-RFA后置入无覆膜SEMS安全可行,作为胰胆管癌闭塞SEMS的支架翻修可能改善TRBO。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In patients with unresectable malignant biliary obstruction (MBO), endoscopic drainage with a self-expandable metal stent (SEMS) is a well-established treatment, but stent patency is limited. This study aimed to evaluate the efficacy of in-stent radiofrequency ablation (IS-RFA) followed by uncovered SEMS placement for the management of occluded SEMSs. METHODS: From 2016 to 2020, 48 patients with recurrent biliary obstruction due to tumor ingrowth or overgrowth after SEMS placement for pancreatobiliary cancer in 3 tertiary hospitals were analyzed. For distal MBO, patients in the RFA group were treated with IS-RFA and uncovered SEMS placement, and those in the control group were treated with uncovered SEMS placement alone. Patients in both groups were matched on the basis of propensity scores in a 1:1 ratio. RESULTS: The median time to recurrent biliary obstruction (TRBO) was 117 days in the RFA group and 82.5 days in the control group (P = .029). No significant differences in median overall survival were detected between the 2 groups (170 days vs 72 days; P = .902). No significant adverse events were reported after the second SEMS placement in either group, but 2 cases of mild cholangitis were reported in the control group. Ablation was interrupted in 5 patients (35.7%) of the RFA group owing to in-stent contact, but sufficient ablative energy was delivered in the majority of the patients (92.9%) after IS-RFA was repeated in the same session. CONCLUSIONS: IS-RFA followed by an uncovered SEMS is safe and feasible and may improve TRBO as a stent revision for occluded SEMSs in pancreatobiliary cancer.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Park N, Jung MK, Kim EJ, et al. In-stent radiofrequency ablation with uncovered metal stent placement for tumor ingrowth/overgrowth causing self-expandable metal stent occlusion in distal malignant biliary obstruction: multicenter propensity score-matched study. Gastrointest Endosc. 2022. PMID: 36460085. doi:10.1016/j.gie.2022.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。